OverviewSuggest Edit

Ironwood Pharmaceuticals (formerly Microbia) is dedicated to creating, developing, and commercializing innovative human medicines, and has clinical-stage programs in GI disorders and dyslipidemia. The Company discovers, develops and commercializes a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood is also developing a pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract.

TypePublic
HQCambridge, US
Websiteironwoodpharma.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2019)317(-38%)
Job Openings16
Revenue (FY, 2019)$428.4 M(+24%)
Share Price (Sept 2020)$9.9 (+3%)
Cybersecurity ratingDMore

Key People/Management at Ironwood Pharmaceuticals

Mark Currie

Mark Currie

Director
Gina Consylman

Gina Consylman

Senior Vice President, Chief Financial Officer
Marla Kessler

Marla Kessler

Director
Andrew Dreyfus

Andrew Dreyfus

Director
Mark Mallon

Mark Mallon

Chief Executive Officer, Director
Jason Rickard

Jason Rickard

Senior Vice President, Chief Operating Officer
Show more

Ironwood Pharmaceuticals Office Locations

Ironwood Pharmaceuticals has offices in Cambridge and Boston
Cambridge, US (HQ)
301 Binney St
Boston, US
100 Summer Street, 100 Summer St #2300
Show all (2)

Ironwood Pharmaceuticals Financials and Metrics

Ironwood Pharmaceuticals Revenue

Ironwood Pharmaceuticals's revenue was reported to be $428.41 m in FY, 2019
USD

Revenue (Q2, 2020)

89.4m

Net income (Q2, 2020)

25.2m

EBIT (Q2, 2020)

32.7m

Market capitalization (14-Sept-2020)

1.6b

Closing stock price (14-Sept-2020)

9.9

Cash (30-Jun-2020)

253.3m

EV

1.8b
Ironwood Pharmaceuticals's current market capitalization is $1.6 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

65.9m150.2m22.9m76.4m149.6m274.0m298.3m346.6m428.4m

Revenue growth, %

234%96%83%

Cost of goods sold

965.0k7.2m25.6m12.0k1.9m19.1m32.8m23.9m

Gross profit

149.3m15.7m50.9m149.5m272.1m279.2m313.9m404.5m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

11.3m12.2m12.2m14.6m96.4m3.3m9.7m4.9m14.6m6.8m16.9m28.9m27.7m39.6m66.0m54.4m66.1m52.2m65.1m86.8m69.2m81.1m65.7m68.7m102.2m131.2m79.9m89.4m

Cost of goods sold

1.2m3.4m2.0m1.9m10.5m12.0k8.2m531.0k3.5m6.1m2.6m4.1m4.6m1.0m11.3m506.0k2.2m

Gross profit

2.0m6.2m2.9m12.7m(3.7m)28.9m19.6m51.6m61.6m80.7m66.5m77.0m61.1m67.7m90.9m130.7m77.7m

Gross profit Margin, %

62%65%59%87%(54%)100%71%99%95%93%96%95%93%98%89%100%97%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

87.3m136.7m75.5m74.3m261.3m54.0m125.7m173.2m177.0m

Accounts Receivable

74.0k457.0k513.0k10.0k2.9m933.0k3.2m21.0m11.3m

Prepaid Expenses

2.9m8.0m6.2m10.6m6.3m7.3m11.1m10.7m

Inventories

6.7m22.1m5.0m1.1m735.0k648.0k
USDQ2, 2011

Financial Leverage

1.9 x
Show all financial metrics

Ironwood Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

D

69/100

SecurityScorecard logo

Ironwood Pharmaceuticals Online and Social Media Presence

Embed Graph

Ironwood Pharmaceuticals Blogs

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call Content Import Mon, 01/28/2019 - 17:03 Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call Jan 28, 2019 This release is a backfill from …

Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation

– Important step toward launching two independent, publicly-traded companies – – Separation on track for first half 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 28, 2019-- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the filing by Cyclerion Therapeutics, Inc.

Michael Shetzline, M.D., Ph.D.

Mike Shetzline joined Ironwood in 2019. He is a gastroenterologist and internist, with more than 25 years of experience in the biopharmaceutical industry and academia. His proven track record is derived from his leadership and experience in all facets of drug development – including discovery resea…

Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation

– Board members bring diverse experience tailored to the distinct opportunities and strategies of each new company – – Julie McHugh to serve as chair of Ironwood board; Marsha Fanucci to serve as chair of Cyclerion board – – Ironwood and Cyclerion expected to have annually elected directors and

Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials

– IW-6463 is one of five Cyclerion sGC stimulators following planned separation – – Data from Phase 1 study expected in second half of 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2019-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced the initiation of a Phase 1 study

Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C

Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C Content Import Tue, 01/15/2019 - 08:05 Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C …
Show more

Ironwood Pharmaceuticals Frequently Asked Questions

  • Who are Ironwood Pharmaceuticals key executives?

    Ironwood Pharmaceuticals's key executives are Mark Currie, Gina Consylman and Marla Kessler.

  • How many employees does Ironwood Pharmaceuticals have?

    Ironwood Pharmaceuticals has 317 employees.

  • What is Ironwood Pharmaceuticals revenue?

    Latest Ironwood Pharmaceuticals annual revenue is $428.4 m.

  • What is Ironwood Pharmaceuticals revenue per employee?

    Latest Ironwood Pharmaceuticals revenue per employee is $1.4 m.

  • Who are Ironwood Pharmaceuticals competitors?

    Competitors of Ironwood Pharmaceuticals include Roivant Sciences, Athersys and Alimera Sciences.

  • Where is Ironwood Pharmaceuticals headquarters?

    Ironwood Pharmaceuticals headquarters is located at 301 Binney St, Cambridge.

  • Where are Ironwood Pharmaceuticals offices?

    Ironwood Pharmaceuticals has offices in Cambridge and Boston.

  • How many offices does Ironwood Pharmaceuticals have?

    Ironwood Pharmaceuticals has 2 offices.